These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34825181)

  • 21. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalent and non-covalent binding of metal complexes to RNA.
    Alberti E; Zampakou M; Donghi D
    J Inorg Biochem; 2016 Oct; 163():278-291. PubMed ID: 27289348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods.
    Moitessier N; Pottel J; Therrien E; Englebienne P; Liu Z; Tomberg A; Corbeil CR
    Acc Chem Res; 2016 Sep; 49(9):1646-57. PubMed ID: 27529781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design.
    Ray S; Murkin AS
    Biochemistry; 2019 Dec; 58(52):5234-5244. PubMed ID: 30990686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Covalent Inhibition of Grb2-Sos1 Interaction through Proximity-Induced Conjugation in Breast Cancer Cells.
    Yu Y; Nie Y; Feng Q; Qu J; Wang R; Bian L; Xia J
    Mol Pharm; 2017 May; 14(5):1548-1557. PubMed ID: 28060514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Covalent binders in drug discovery.
    Vasudevan A; Argiriadi MA; Baranczak A; Friedman MM; Gavrilyuk J; Hobson AD; Hulce JJ; Osman S; Wilson NS
    Prog Med Chem; 2019; 58():1-62. PubMed ID: 30879472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in Covalent Drug Discovery.
    Schaefer D; Cheng X
    Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent drugs targeting histidine - an unexploited opportunity?
    Che J; Jones LH
    RSC Med Chem; 2022 Oct; 13(10):1121-1126. PubMed ID: 36325394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A covalent BTK ternary complex compatible with targeted protein degradation.
    Schiemer J; Maxwell A; Horst R; Liu S; Uccello DP; Borzilleri K; Rajamohan N; Brown MF; Calabrese MF
    Nat Commun; 2023 Mar; 14(1):1189. PubMed ID: 36864023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.
    Lee J; Park SB
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinguishing the optimal binding mechanism through reversible and irreversible inhibition analysis of HSP72 protein in cancer therapy.
    Aljoundi A; El Rashedy A; Soliman MES
    Comput Biol Med; 2021 May; 132():104301. PubMed ID: 33751994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Chloropropionamide As a Low-Reactivity Electrophile for Irreversible Small-Molecule Probe Identification.
    Allimuthu D; Adams DJ
    ACS Chem Biol; 2017 Aug; 12(8):2124-2131. PubMed ID: 28613814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate.
    Anand U; Bandyopadhyay A; Jha NK; Pérez de la Lastra JM; Dey A
    Biofactors; 2023 Mar; 49(2):251-269. PubMed ID: 36326181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors.
    Li B; Rong D; Wang Y
    Curr Top Med Chem; 2019; 19(21):1872-1876. PubMed ID: 31696799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.